Monday, 5 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

The Sales Test This Norwest Partner Gives Founders Before He’ll Invest

View original at news.crunchbase.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Before investing, Jacobsohn goes on sales calls with the CEO to assess the founder's selling ability, which he considers a major indicator of a company's potential.

    60% confidence
  • AI should not be trusted to perform calculations in finance because it is not good at math and errors can occur.

    60% confidence
  • It would be very hard to disrupt the core products of Workday, ADP, SAP, UKG and Dayforce, but easier to disrupt their secondary, non-core products.

    60% confidence
  • Jacobsohn built the Failure Museum, containing more than 1,500 items from failed companies and products, to study why they failed.

    60% confidence
  • Because CFOs buy software for themselves with one less layer of approval, it is easier to replace that software when the CFO is the direct buyer.

    60% confidence
  • There is a potential opportunity to disrupt NetSuite and Sage in ERP, with disruption happening more downmarket first before moving upmarket.

    60% confidence
  • Norwest's Office of the CFO market map has more than 500 companies, about three-quarters of which are legacy players.

    60% confidence
  • Norwest's primary entry point is seed and Series A, with opportunistic participation in later Series B and C deals.

    60% confidence
  • Jacobsohn has passed on CEOs/startups when the founder was consistently unable to secure second meetings on sales calls.

    60% confidence
  • An acquisition for less than $1 billion can still be a great outcome given Norwest's early entry point and typical acquirer budgets.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com